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Abstract
Background: Recombinant adenoviruses are employed to deliver a therapeutic transgene in the
liver, muscle or tumour tissue. However, to rationalise this delivery approach, the factors of
variation between individuals need to be identified. It is assumed that differences between inbred
strains of laboratory animals are considered to reflect differences between patients. Previously we
showed that transgene expression in the liver of different rat strains was dependent on the
transcription efficiency of the transgene. In the present paper we investigated if transfection of
muscle and tumour tissue were also subject to such variations.
Methods: Variation, in transgene expression, after intramuscular gene delivery was determined in
different rodent strains and gene expression in tumours was investigated in different human and
rodent cell lines as well as in subcutaneously implanted rodent tumours. The molecular
mechanisms involved in transgene expression were dissected using an adenovirus encoding
luciferase. The luciferase activity, the viral DNA copies and the luciferase transcripts were assessed
in cultured cells as well as in the tissues.
Results: Large differences of luciferase activity, up to 2 logs, were observed between different
rodent strains after intramuscular injection of Ad Luciferase. This inter-strain variation of transgene
expression was due to a difference in transcription efficiency. The transgene expression level in
tumour cell lines of different tissue origin could be explained largely by the difference of infectibility
to the adenovirus. In contrast, the main step responsible for luciferase activity variation, between
six human breast cancer cell lines with similar phenotype, was at the transcriptional level.
Conclusion: Difference in transcriptional efficiency in muscles as observed between different
inbred strains and between human breast cancer cell lines may be expected to occur between
individual patients. This might have important consequences for clinical gene therapy. The variation
between tumour types and tissues within a species are mainly at the levels of infectivity.
Background
In an attempt to increase efficacy and decrease toxicity,
new drugs are designed to interact with unique or specific
cellular pathways. Therefore the expected responders are
likely to be a subpopulation of patients falling under one
diagnosis but with a specific targeted pathway; e.g. Her-
ceptin in the HER2-positive patients with a breast cancer.
However, this subpopulation bearing the targeted recep-
tor or the specific pathological pathway still includes
patients that are poor responders to the treatment. One of
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the reasons for that may be the inter-individual variation
of susceptibility to the tested drug. For example, many
xenobiotics are metabolised at different rate in the liver
from one individual to the other. The targeted pathway,
through the receptor of the drug or the cofactors involved,
may also vary in the population. The new molecular tech-
nologies enable to screen the population for genotypic
variation of the gene or genes involved in the control of
those pathways. When these parameters are elucidated,
the responsiveness of individual patients to the drug can
be predicted. On the one hand this knowledge might be
used to adapt the dose to the individual patient in order
to increase the drug efficacy and to avoid adverse effects.
On the other hand this pharmacogenetic knowledge can
be used to identify a subpopulation of patients that would
respond better to the treatment without adverse effects.
There is evidence that not only responses to xenobiotics,
but also to non-viral and viral vectors, are subject to sig-
nificant inter-individual variation. Indeed, clinical trials
using gene therapy were hindered by inter-individual var-
iation leading either to lack of therapeutic effect or to
unexpected toxicity [1,2]. In the case of adenoviral gene
therapy, the causes of these inter patient variation are only
partially clarified. Several studies showed the crucial role
of neutralising antibody (nab) against viral vectors [3–5].
Anti-Ad5 nab titers vary greatly in the population and its
determination is now generally accepted as obligatory to
adjust the Ad5 dose [6–8]. However, this is probably not
the only factor that influences gene transfer efficiency
between individuals. The present study is an attempt to
determine where the variation occurs after the gene trans-
fer, from the penetration of the virus in the cell to the syn-
thesis of the encoded protein. The magnitude of variation
between the response of patients to gene therapy is diffi-
cult to establish because it requires large numbers of indi-
viduals and because this type of gene transfer studies with
healthy volunteers are problematic. The genetic differ-
ences observed between inbred strains of animals assum-
edly reflect differences between individuals of an outbred
strain. Accordingly, we decided to explore the issue using
inbred strains of rodents and human cell lines.
Several investigators have reported large variations of
transgene expression between inbred mouse strains after
intravenous administration of a recombinant adenovirus
to naïve animals [9–13]. The main tissue that is trans-
fected after intravenous administration of a recombinant
adenovirus is the liver. In a previous paper, we have
described differences between three rat strains in trans-
gene expression efficiency in the liver [14]. In order to
determine which step was involved in this variation, the
transfection machinery of the liver was dissected. It was
demonstrated that the differences of transgene expression
occur not at the level of penetration of the virus into the
cell, but at the transcriptional level. Indeed the transcrip-
tion efficiency in the liver, which comprises both mRNA
synthesis and stability, differed up to one log between the
rat strains. Many clinical application of gene therapy
involve tumour transfection or intramuscular gene trans-
fer. However variations of transgene expression were
poorly documented in such clinical investigations, princi-
pally because these trials are mainly focused on the toxic-
ity and the therapeutic efficacy of the gene transfer.
Nevertheless, large variations of transgene expression
between cultured tumour cells were reported by several
investigators [8]. Such variations were also observed
between mouse strains after muscle transfection [15,16].
Therefore, the present study attempts to determine the
causes of such variation after transfection of tumour and
muscle tissue.
Results
Gene transfer in muscle
An impressive difference in muscular expression between
rat strains was first observed with adenoviral vectors that
contain the transgenes for endostatin, ATF-BPTI and ATF
(Fig. 1). After intra muscular injection of the vector, the
plasma levels of the encoded proteins rose to one log
higher in Wag/Rij rats than in Brown Norway rats. To
investigate if this phenomenon was indeed due to a differ-
ence in muscular production of the encoded protein the
marker gene luciferase was employed. In order to expand
this strain specificity of transgene expression a third strain,
the Fisher rat, was also included in the experiments. At all
3 vector doses a difference in luciferase expression was
noted between the strains (Fig. 2). At 1010iu Ad luciferase,
as for the preceding transgenes, the difference was also
one log between the Wag/Rij and the Brown Norway rats.
Thus, the difference of plasma levels of the secreted
encoded-proteins is most likely explained by differences
in their rate of synthesis in the muscle.
In order to determine if the infection of the myocytes dif-
fers from one strain to the other, the number of Ad DNA
copies was determined in the muscle after injection with
the luciferase vector. The amount of Ad DNA copies
detected by real time PCR in the gastrocnemius was about
3 to 9 % of the dose injected (Fig 3). According to Scheffe's
test the differences between the three rat strains were not
significant. The muscle is almost exclusively composed of
myocytes and the adenoviral DNA detected in the muscle
tissue should reflect infection of myocytes. This strongly
suggests that a similar amount of adenovirus transfected
the muscle in the three rat strains. However, adenovirus
particles in apoptotic myocytes or phagocytosed by
immune cells would not contribute to the luciferase pro-
duction. Therefore, to exclude that a massive rhabdomy-
olysis or a severe inflammatory infiltrate in the
gastrocnemius is causing the difference of luciferase
expression, the histology of the muscles and the serumBMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/11
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levels of creatine phosphokinases (CPK) were assessed at
2 days after injection. In all 3 strains a mild inflammatory
infiltrate was observed in the muscle, but almost no cell
necrosis (Table 1 and 2). Scoring of the damage by a
pathologist did not reveal differences between the rat
strains. The CPK were only two times the normal value.
Seemingly, the difference in luciferase expression is due to
processes that occur somewhere after the penetration of
the virus into the cells.
Transgene expression in the plasma after intra-muscular gene  delivery Figure 1
Transgene expression in the plasma after intra-muscular gene 
delivery. Plasma levels of endostatin (yellow bars), mhATF-
BPTI (blue bars) and ATF (red bars) in Wag/Rij rats (A) and 
in Brown Norway rats (B) after intra muscular injection of 
1010 iu Ad5 Adapt encoding the respective transgenes. Ten 
animals per group, data are expressed as mean ± SD. The 
higher levels of endostatin compared to the ATF and ATF-
BPTI is due to the pharmacokinetic characteristics of these 
molecules.
Luciferase expression in the gastrocnemius muscle of 3 rat  strains after intra-muscular delivery Figure 2
Luciferase expression in the gastrocnemius muscle of 3 rat 
strains after intra-muscular delivery. Luciferase activity was 
determined 48 hours after intra-muscular injection of 109 iu 
(white bars, n = 6), 3 109 iu (striped bars, n = 4), and 1010 iu 
(black bars, n = 9) Ad5 Adapt Luc. The mass of the gastroc-
nemius is similar in the 3 strains. Data are expressed as mean 
± SD. The value of the mean is shown above the bars.
Infectibility of the gastrocnemius muscle to the adenoviral  vector in the 3 rat strains Figure 3
Infectibility of the gastrocnemius muscle to the adenoviral 
vector in the 3 rat strains. The same muscles were used as in 
Fig. 2. The number of Adenoviral DNA copies per muscle 
was determined by duplex real time PCR. The number of 
DNA copies was determined in a sample of a homogenate of 
the whole gastrocnemius muscle and then extrapolated to 
the total mass of the gastrocnemius. Data are expressed as 
mean ± SD. The value of the mean is shown above the bars.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/11
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The next step to investigate was the levels of luciferase
mRNA. For this purpose the gastrocnemius of the rat is
too large to be processed in one time and the extraction of
mRNA would be cumbersome and subject to error. To
avoid these inconveniences, we decided to switch to mice.
The gastrocnemius muscle of a mouse is large enough to
be injected with the required volume of adenoviral sus-
pension and small enough to be processed as a whole for
RNA extraction. We studied 6 different mouse strains with
different genetic background. The animals were injected
with Ad luciferase in the gastrocnemius and the muscle
was harvested 2 days later for luciferase measurement,
DNA and RNA extraction. Large differences in luciferase
activity were measured between the mouse strains and the
range of values was even greater than that observed in the
rats (Fig 4A). DBA mice showed the lowest transgene
expression whereas the luciferase activity was 60 times
higher in C57BL/6 mice. The creatine phosphokinases
(CPK) level in the plasma is correlated to the degree of
muscle fiber damage [17,18]. Thus, the plasma CPK was
measured at the time of sacrifice, in order to verify that the
low luciferase values were not caused by massive rhab-
domyolysis. The CPK plasma levels were only slightly ele-
vated and roughly similar in all strains (Table 3). Similar
to the situation observed in rats, the number of adenoviral
DNA copies in the injected gastrocnemius was also not
Table 1: Criteria for scoring muscle damage. The pathological changes were graded on 4 transversal sections of the right gastrocnemius. 
The total damage score is a compilation of scores of apoptosis, hyaline degeneration, myoblasts regeneration, and inflammation. All 
scores are ranging from 0 to 3.
Score
0123
Apoptosis Number of apoptotic cells / bodies in 
10 random 20 × magnification fields
0–1 <5 5–13 >13
Hyaline degeneration Percentage of fibers 
affected.
0–1% 1–10 % 10–50% > 50%
Myoblasts Number of myoblasts in 10 random 20 
× magnification fields
0–1 <5 5–13 >13
Inflammation Diffuse or multifocal inflammation 
in muscle fibers
Normal background Increase of 
inflammatory cells
Aggregates of 
inflammatory cells
Aggregates of 
inflammatory cells 
obscuring the muscle 
architecture
Table 2: Muscle damage caused by injection of adenovirus in rats. The muscle lesions were assessed, as described in table 1, two days 
after the intramuscular injection of the adenoviral vector. The total muscle inflammation and damage scores range from 0–3 and 0–12 
respectively. 4 animals per group. The CPK were measured 2 days after the vector injection. Values show the mean ± SD.
High dose (1010iu)
Brown Norway Wag / Rij
Total muscle inflammation 1.2 ± 0.5 1.0 ± 0.8
Total muscle damage 2.2 ± 0.5 2.4 ± 0.8
Total muscle proteins (mg/g tissue) 85 ± 22 77 ± 33
CPK in plasma (IU) 950 ± 205 1096 ± 173
Table 3: Creatine phosphokinase (CPK) concentrations in the plasma of mice. The CPK were determined in the plasma of the mice 2 
days after viral administration in the muscle (N = 4) and in untreated control animals (N = 3). Data were derived from the same 
experiment as depicted Fig 4.
CPK (IU)
Strains: BALB/c C57BL/6 CBA DBA NOD/scid C3H
Treated mice 1570 ± 427 1248 ± 391 1427 ± 342 1291 ± 225 1332 ± 258 1343 ± 217
Control mice 405 ± 72 455 ± 143 316 ± 15 443 ± 83 401 ± 78 405 ± 72BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/11
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statistically different between the mouse strains (Fig 4B).
The quantification of luciferase transcripts was performed
by Northern blotting (Fig 5). All the mouse strains
showed similar amounts of total RNA and β-actin mRNA
in the gastrocnemius, but different amounts of luciferase
mRNA. The amount of luciferase transcript was propor-
tional to the luciferase activity. Therefore, the differences
in encoded protein expression in the muscle are due to
differences in transcription efficiency, including mRNA
synthesis or / and stability.
Gene transfer in tumours
Tumours are composed of tumour cells and of various
infiltrating stroma cells. It was shown that mainly tumour
cells are infected after intratumoral delivery of a recom-
binant adenovirus encoding the β-galactosidase gene, and
that the transfection of the stroma cells seems not to be
Variation among mouse strains in transgene expression and  infectibility to adenovirus after intra-muscular injection Figure 4
Variation among mouse strains in transgene expression and 
infectibility to adenovirus after intra-muscular injection. The 
animals were injected with 3 109 iu Ad5 Adapt Luc in the 
right gastrocnemius. A: Luciferase activity. B: Number of 
Adenoviral DNA copies per muscle determined by duplex 
real time PCR. The number of DNA copies was determined 
from a sample of a homogenate of the whole gastrocnemius 
muscle and then extrapolated to the total muscle mass. Data 
are expressed as mean ± SD. The value of the mean is shown 
above the bars.
Luciferase transcripts in mouse muscles after intra-muscular  injection Figure 5
Luciferase transcripts in mouse muscles after intra-muscular 
injection. Quantification of the luciferase mRNA in the mus-
cle of the mice injected with 3 109 iu Ad Adapt Luc by North-
ern blotting. These data refer to the muscles as depicted in 
Fig. 4. The RNA was extracted from a homogenate of the 
whole gastrocnemius and a northern blot was performed. 
The density of the bands was determined with a phosphorim-
ager. Mean values ± SD, depicted on the figure, are 
expressed in arbitrary units. The mouse strain is indicated on 
the figure. Lane 1–6, 9–13, 16–20, 23–26, 29–33, 36–39: ani-
mals injected with Ad5 Adapt Luc. Lane 7–8, 14–15, 21–22, 
27–28, 34–35, 40–41: animals injected with 3 109 iu Ad5 
Adapt Empty. Lane 42: negative control plasmid. The ampli-
con product is 310 base pair. The density of the β-Actin tran-
scripts bands was also quantified and proved to be similar in 
all the animals (825 ± 74).BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/11
Page 6 of 15
(page number not for citation purposes)
significant (unpublished data). Nonetheless we studied 8
rodents tumours with less than 20% of stroma. We
showed that the transgene expression in these tumours in
vivo merely corresponds with that of the tumour cell lines
in culture (Fig 6). This finding suggests that information
collected with human tumour cell lines is likely to reflect
the transduction of the corresponding human tumours in
vivo. Therefore the variation observed with cultured cell
lines may give us some insight in the variation among
patient tumours. We studied the transduction in cell lines
of different tissue types and within a certain tissue type,
namely mammary cancer.
Comparison of in vitro and in vivo gene transfer in tumours Figure 6
Comparison of in vitro and in vivo gene transfer in tumours. 
A: Luciferase activity in rats and mouse tumours 48 hours 
after intratumoral injection of 1010 iu Ad5 Adapt Luc (n = 5). 
The tumours are growing subcutaneously, and were about 8 
× 8 mm at the time of injection. Values indicate means ± SD. 
B: Luciferase activity measured in lysate of cell cultures 48 
hours after in vitro infection with Ad Adapt Luc at different 
MOI. Values are mean of a triplicate ± SD.
Luciferase activity, viral DNA and luciferase mRNA in differ- ent human cancer cell lines after adenoviral transfection Figure 7
Luciferase activity, viral DNA and luciferase mRNA in differ-
ent human cancer cell lines after adenoviral transfection. A: 
Luciferase activity measured in cell lysate 48 hours after 
infection with different MOI. B: Number of Adenoviral DNA 
copies per cell determined by duplex real time PCR. The 
number of cells was determined by microscopic counting and 
the number of genome by real time PCR of the GAPDH 
gene. All cell lines had similar ploidy. C: Quantification of the 
luciferase mRNA in the cell lines after infection at different 
MOI by Northern blotting. The density of the bands was 
determined with a phosphorimager. The β-actin blotting was 
also performed afterwards to control the quality of the RNA 
extraction and the quantity of RNA loaded. The density of 
the β-actin bands was similar in all the cell lines (data not 
shown). Values indicate mean of a triplicate ± SD.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/11
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Human and rodent tumour cell lines of different tissue
origins were employed to study the molecular steps lead-
ing to encoded protein synthesis. Huge differences in
transgene expression, up to a magnitude of 2 logs, were
measured between human and rat tumour cell lines (Fig
7A and 8A). Among the human tumour cells, the U251
Glioma showed the highest expression, whereas the LS
174T colon adenocarcinoma expressed the lowest
luciferase activity. To roughly determine at which steps
these differences reside, the amount of adenoviral DNA
and luciferase transcripts were quantified. As depicted in
Fig 7B and 8B a wide range of infectibility to the adenovi-
rus, defined as the proportion of adenoviral copies that
entered the cell, was observed in this panel of cell lines.
The Glioma U 251 was very permissive to infection by
adenovirus as nearly all the infectious units that were
added to the culture were retrieved in the cells 2 days later.
In contrast, only 0.5–1% of the seeded adenoviruses
infected the LS 174T cells. The luciferase mRNA was deter-
mined (Fig 7C and 8C) and the results showed that the
RNA levels corresponded with the DNA levels and luci-
ferase activity and consequently that the transcription effi-
ciency was very similar for all cell lines except for the A459
which showed a 5 time lower efficiency (Table 4). The
translation efficiency (ratio of luciferase per transcript),
even if statistically different between the cell lines, did not
vary in the same proportion as the transgene activity
(Table 4). The A549 had the lowest translation efficiency
but the U251 had only a 4 time higher efficiency. In all
cases, excepted for the A549, the variation in transgene
expression between the cell lines can be attributed to a dif-
ference in infectibility. The A459 cell line produced
slightly more luciferase (3 times) than the LS 174T but
had a much higher infectibility (36 times) and a 5 and 2
times lower transcription and translation efficiency,
respectively.
To address the issue of variation within a single tumour
type, we used 6 human breast cancer cell lines. All these
cell lines showed a similar phenotype. Indeed, the cyto-
logical examination revealed glandular formation typical
of ductal adenocarcinomas in all of them (Fig 9). These
cell lines were infected in vitro with the Ad Adapt Luc
using a range of MOIs. The different steps of gene expres-
sion were investigated as described before. The luciferase
measurements showed a very large variation between the
cell lines with differences up to 2 logs (Fig 10). All the
breast cancer cell lines were very susceptible to adenoviral
infection and contained similar amounts of viral DNA
(Fig 10 Table 5A). In contrast to cells of different tissue
origin, the variation of transgene expression among the
breast cancer cell lines is not explained by differences of
infectibility. Furthermore the luciferase mRNA content of
the cells was proportional to the luciferase activity (Fig
10) and accordingly the translation efficiency was similar
in all cell lines (Table 5C). However, these adenocarci-
noma cell lines with similar infectibility and translation
efficiency have different transcription efficiency (Table 5).
Gene transfer in two rat cancer cell lines Figure 8
Gene transfer in two rat cancer cell lines. A: Luciferase activ-
ity measured in cell lysate 48 hours after infection at different 
MOI. B: Number of Adenoviral DNA copies per cell deter-
mined by duplex real time PCR. The number of cells was 
determined by microscopic counting. C: Quantification of the 
luciferase mRNA by Northern blotting. The densities of the 
luciferase and β-actin blots were determined with a phos-
phorimager. Values show mean of a triplicate ± SD.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/11
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Thus, in case of tumour cell line of similar histological ori-
gin (in our study breast cancer cell lines), the difference of
transgene expression might be due to different
transcriptional efficiency and not to difference in suscep-
tibility to infection.
Discussion
Adenoviruses are attractive vectors for gene therapy due to
their high transfection efficiency in a large number of tis-
sues and their relatively easy production at a large scale.
However, there are still some drawbacks that hinder their
clinical application. The first factor that was recognised to
Table 4: Transgene expression in different human cancer cell lines. These values are determined in the same experiments as depicted 
in figures 7 and 8. A: Infectibility of the cell lines as defined by the percentage of adenovirus DNA seeded that was detected in the cells 
2 days after infection. B: the transcription efficiency is defined by the ratio of the mRNA values divided by the number of adenoviral 
copies in the cells. C: The translation efficiency is the ratio of the luciferase activity / luciferase mRNA. D: Luciferase activity in 103 RLU 
/ mg protein. The absolute values are shown in italic. The values relative to the LS174T, which was arbitrary set as reference are 
indicated in plain text.
A
Infectibility (% Ad in cell / Ad seeded)
MOI Cell lines
U251 NCI H460 HepG2 A549 LS 174T
1 72 82 13 15 12 14 34 38 0.9 1
10 55 104 7 13 10 18 21 40 0.5 1
100 78 101 10 13 9 12 22 29 0.8 1
A v e r a g e 9 61 41 53 6 1
S D1 2 136
B
Transcription efficiency (mRNA / Ad DNA
MOI Cell lines
U251 NCI H460 HepG2 A549 LS 174T
1 2.1 0.7 2.1 0.8 2.0 0.7 0.4 0.14 2.8 1
10 2.0 0.7 2.7 0.9 1.9 0.7 0.4 0.16 2.8 1
100 1.9 0.7 2.7 1.0 2.3 0.9 0.6 0.22 2.6 1
Average 0.72 0.91 0.76 0.17 1
SD 0.02 0.14 0.11 0.04
C
Translation efficiency (Luciferase / mRNA)
MOI Cell lines
U251 NCI H460 HepG2 A549 LS 174T
1 40 2.8 12 0.8 13 0.9 9 0.6 14 1
10 127 2.2 48 0.8 38 0.7 28 0.5 58 1
100 316 1.6 152 0.8 140 0.7 78 0.4 198 1
Average 2.2 0.8 0.8 0.5 1
SD 0.6 0.04 0.2 0.1
D
Luciferase activity
MOI Cell lines
U251 NCI H460 HepG2 A549 LS 174T
1 60 172 3 9.2 3 9.5 1 3.4 0.3 1
10 1381 158 92 10.5 69 7.9 27 3.1 9 1
100 46350 116 4061 10.1 3055 7.6 1016 2.5 400 1
Average 149 9.9 8.3 3.0 1
SD 29 0.7 1.0 0.4BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/11
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limit adenoviral gene therapy was the presence of neutral-
ising antibodies. Measures have been implemented to
overcome this limitation, such as developing vectors that
evade the immune system. In this report we highlight
other factors that should be taken into account for the
clinical application of gene therapy. The first factor is the
variable transcription efficiency (level of transcript accu-
mulation) between individuals after transfection of a spe-
cific tissue like the liver or muscles. There is no clear
indication in the literature whether this variation is spe-
cific to one promoter or is this phenomenon general for
all promoters. However, viral promoters are usually sensi-
tive to cytokines and it is known that they influence the
transcription efficiency. Furthermore, it was recently
shown that transcriptional repression of the CMV pro-
Cytology of the different human breast cancer cell lines Figure 9
Cytology of the different human breast cancer cell lines. The 
photographs show cell cultures of the different breast cancer 
cell lines (magnification × 200). All cell lines develop a glandu-
lar phenotype: cuboid cell shape and clusters of few cell lay-
ers around a canalicule formation (black arrows).
Luciferase activity and viral DNA in human breast cancer cell  lines Figure 10
Luciferase activity and viral DNA in human breast cancer cell 
lines. A: Luciferase activity measured in cell lysate 48 hours 
after infection at different MOI. B: Number of Adenoviral 
DNA copies per cell determined by duplex real time PCR. 
The number of cells was determined by microscopic count-
ing and the number of genome by real time PCR of the 
GAPDH gene. All the cell lines had similar ploidy. C: Quanti-
fication of the luciferase mRNA in the cell lines after infection 
at different MOI by Northern blotting. The density of the 
bands was determined with a phosphorimager. The β-actin 
blotting was also performed afterwards to control the quality 
of the RNA extraction and the quantity of RNA loaded. The 
density of the β-actin bands was similar in all the cell lines 
(data not shown). Values are means of a triplicate ± SD.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/11
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moter induces interspecies variation of the transgene
expression [19]. However this poorly understood phe-
nomenon, known as promoter interference, seems to be
specific for retroviral vectors and was only observed
between species. In addition we identified a tissue-specific
variation, which occurs at the level of infection only as
well as in addition at the transcriptional level (Table 6).
From intra-muscular protein vaccination it is known that
the amount of antigen used influences the type of
immune response. A low level of antigen will elicit only
Table 5: Transgene expression in breast cancer cell lines. These values are determined in the same experiments as depicted in figures 
10 and 11. A: Infectibility of the cell lines as defined by the percentage of adenovirus DNA seeded that was detected in the cells 2 days 
after infection B: the transcription efficiency is defined by the ratio of the mRNA values divided by the number of adenoviral copies in 
the cells. C: The translation efficiency is the ratio of the luciferase activity / luciferase mRNA. D: Luciferase activity in 103 RLU / mg 
protein. The absolute values are indicated in italic. The values relative to the ZR 75.1, which was arbitrary set as reference are indicated 
in plain text.
A
Infectibility (% Ad in cell / Ad seeded)
MOI Cell lines
EVSA-T CAMA-1 MCF-7 T47 D SKBR-3 ZR 75.1
1 7 1.1 6 1.0 6 1.1 6 1.0 6.7 1.1 6.0 1
10 6 1.2 5 1.1 6 1.2 4 0.8 4.8 1.0 4.9 1
100 9 1.2 9 1.2 9 1.3 8 1.0 7.9 1.1 7.3 1
Average 1.2 1.1 1.2 1.0 1.1 1
SD 0.0 0.1 0.1 0.11 0.1
B
Transcription efficiency (mRNA / Ad DNA)
MOI Cell lines
EVSA-T CAMA-1 MCF-7 T47 D SKBR-3 ZR 75.1
1 213 55 71 18 27 6.8 9 2.2 9.5 2.4 3.9 1
10 176 61 49 17 19 6.6 9 3.2 8.0 2.8 2.9 1
100 137 56 41 17 12 5.0 6 2.4 6.0 2.5 2.4 1
Average 57.2 17.4 6.1 2.6 2.6 1
SD 3.4 0.8 1.0 0.5 0.2
C
Translation / post translation efficiency (Lucieferase / mRNA)
MOI Cell lines
EVSA-T CAMA-1 MCF-7 T47 D SKBR-3 ZR 75.1
1 2 1 2 1 3 1.2 4 1 . 641 . 6 2.4 1
10 6 1 6 1 6 1.0 8 1 . 461 . 0 6.0 1
100 26 2 38 2 33 2.0 15 0 . 91 30 . 8 16.2 1
Average 1.2 1.4 1.4 1.3 1.1 1
SD 0.4 0.8 0.6 0.4 0.4
D
Luciferase activity
MOI Cell lines
EVSA-T CAMA-1 MCF-7 T47 D SKBR-3 ZR 75.1
1 28 50 10 18 5 8 2 4 2 4.4 1 1
10 620 74 167 20 65 8 32 4 22 2.7 8 1
100 30473 105 13171 46 3790 13 648 2 616 2.1 289 1
Average 76.4 28 9.7 3.2 3.0 1
SD 27.8 15 2.9 0.8 1.2BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/11
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cellular immunity but no neutralising antibodies. There-
fore, it is of importance for DNA vaccination approaches
to control the quantity of antigen that is produced in the
muscle after gene transfer. The study of adenoviral gene
delivery in the muscle is more cumbersome than for the
liver. The principal reason is that the transfection is very
inhomogeneous after intra-muscular injection. Some
parts of the muscle are very poorly infected if at all,
whereas the majority of the fibers around the needle track
are transfected. Therefore the whole of the injected muscle
has to be homogenised to get an indication of the degree
of transfection. Secondly, the different parameters (Luci-
ferase activity, DNA or mRNA amount) cannot not be
determined per muscle cell. Indeed, the number of myo-
cytes per mg muscle cannot be accurately determined as
the cellular volume and the number of nuclei varies
greatly between muscle fibers. Therefore, the parameters
have to be expressed per whole muscle. It was demon-
strated that the huge difference in transgene expression
between the different strains was explained by difference
of transcription efficiency. Extrapolated to the clinical sit-
uation this would mean that antigen production and
therefore the expected immune response after intra-mus-
cular vaccination with adenovirus might also differ widely
between patients. In humans and in large animals the
transfection efficiency cannot not be assessed by muscle
biopsy. Due to the inhomogeneous distribution of the
transfection, one cannot perform the biopsy in such a way
that all of the transfected muscle is recovered. One possi-
ble way to circumvent this obstacle is to identify a circu-
lating surrogate marker of transfection.
Tumours are composed of cancer cells and of a variety of
infiltrating cells. The latter non-neoplastic cells include
endothelial cells, fibroblasts, and inflammatory cells. The
composition and the proportion of these infiltrating cells
vary greatly from one tumour to the other. Some tumour
types, like glioma's, contain few infiltrating cells whereas
epithelioma's are usually infiltrated by a large amount of
fibroblasts. This variation is also found between patients
with histologically identical tumours. After local gene
delivery, the contribution of these cells to the production
of the encoded protein has not yet been evaluated. Thus,
different tumour compositions between patients might
also be a factor of variability of intra tumoral gene
transfer. Therefore in vitro cell culture appeared to be
more representative to study the variation of tumour cell
transfection per se. However it is claimed that the mem-
brane receptors for adenovirus might be down regulated
in culture and gene transfer would consequently be lower.
However, this would interfere only with the penetration
of the vector into the cells. We have shown that breast
cancer cell lines with similar numbers of transgene copies
may present large differences of transgene expression and
that this was due to different transcriptional efficiency.
Furthermore, it should be noted that within one cell type
the infectibility and the transcription efficiency are inde-
pendent of the moi, but the translation efficiency
increases significantly with the moi and consequently the
encoded protein activity. This phenomenon is particularly
marked in human cell lines as compared to rat cells.
In the case of intra-tumoral delivery, preexisting immu-
nity against the viral vector may be of less importance
than it is for muscle gene transfer. It was shown in animal
models that the presence of neutralising antibodies did
not completely impair gene transfection after intratu-
moral delivery (unpublished data, [20,21]). In patients
the situation is also not clear, as therapeutic efficacy of
gene therapy has been reported in patients with titers of
nab, high enough to completely neutralise the viruses if
administrated intravenously. Thus, apart from the varia-
tion in neutralizing antibodies titers it is suggested that
different transcriptional efficiency might be the cause of
large inter-patient differences in responsiveness to
intratumoral gene therapy. Therefore, future clinical stud-
ies should not only include the determination of the
transfection of the targeted organs by measuring the viral
DNA but also an assessment of the locally encoded pro-
tein production.
Methods
Animals
Pathogen-free inbred male Wag/Rij and Brown Norway
rats, weighing 300 to 350 gr and male C57BL/6, Balb/c,
C3H, CDA, CBA, and NOD/scid mice weighing about
20gr were purchased from Harlan, The Netherlands. All
animals were fed ad libitum with laboratory chow and
water and were kept under standard laboratory condi-
tions. The intra muscular injections were performed in the
right gastrocnemius of the animals. The volume injected
was 50 µl for the mice and 100 µl for the rats. It was veri-
fied that 98% of the transgene expression occurs in the
gastrocnemius and the rest in the surrounding muscles.
Table 6: Assumptions concerning the origin of the variation of 
transgene expression after adenoviral transfection.
Transfection Variation
Different Tissues Infection
w / wo
Transcription
Different Individuals Transfection
The difference of transgene expression between tissues of different 
histological origin is mainly due to differences in infectibility coupled in 
some cases with differences in transfection efficiency. The infectibility 
of a specific tissue is similar between individuals. However the 
transcription efficiency may vary greatly with subsequent large 
difference of transgene expression between two individuals.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/11
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All animal procedures were performed in accordance with
the official guidelines after obtaining permission of the
animal welfare committee.
Tumours
The tumours in the Wag /Rij rats are the L42 bronchial
squamous carcinoma, the L37 bronchial adenocarci-
noma, and the CC531 colon adenocarcinoma [22,23].
The L44 is an anaplastic lung tumour in Brown Norway
rats [24]. The II-45 is a malignant mesothelioma in the
Fisher 344 rats [25]. The B16F10 (ATCC#: CRL-6475) is a
melanoma in the C57BL/6 mice. The C26 coloncarci-
noma (ATCC#: CRL-2638) and the TSA breast adenocarci-
noma are growing in the BALB/c mice. The TSA was a kind
gift of Dr. T deVries (University of Leiden, The
Netherlands).
The U251 human glioma cell line was obtained from the
American Type Culture Collection. The NCI-H460
(ATCC#: HTB-177) is a human non-small cell lung
carcinoma cell line derived from the pleural fluid of a
patient with large cell cancer of the lung [26]. The A549
cell line (ATCC#: CCL-185) is derived from an alveolar
lung carcinoma with properties of type II pneumocytes
[27]. The HepG2 (ATCC#: HB-8065) is a human hepato-
cellular carcinoma cell line. The LS 174T (ATCC#: CL-
188) is a human colon adenocarcinoma cell line [28].
All the human breast cancer cell lines were kindly pro-
vided by Dr A. Sieuwerts (University Hospital Rotterdam,
The Netherlands). The EVSA-T cells were derived from
malignant ascitic effusion from a female patient with met-
astatic infiltrating ductal breast carcinoma [29]. The
SKBR-3, MCF-7, SK-BR-3, ZR75-1, and the CAMA-1 cell
lines were established from pleural effusions of patients
suffering from a breast cancer [30–33,32].
All the cell lines were cultured in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% FBS.
When the cells reached 80% of confluence, they were
trypsinised, washed, resuspended in PBS and used for fur-
ther in vitro or in vivo experiments.
Adenoviral vectors
Recombinant adenovirus vectors were generated in
PER.C6™ cells by homologous recombination between an
adapter plasmid (pAdapt) and the E1 deleted Ad 5 DNA
plasmid as described elsewhere [34]. The expression cas-
sette contains a CMV promoter and SV40 poly A signal. As
a result of the absence of sequence overlap between the
Adapt plasmid and the Ad5 E1 sequences integrated into
the genome of PER.C6, the vector stocks used in this study
did not contain replicative competent adenovirus (RCA)
[35].
The Ad5 Adapt mhAB encodes for a murinised form of the
human ATF-BPTI (mhAB) [36]. In this construct the
mhATF-BPTI, is preceded by the native secretion signal
peptide of the human urokinase. The human endostatin
coding sequence (InvivoGen, CA, USA) was cloned in the
Ad5 Adapt shuttle vector. The encoded endostatin corre-
sponds to the 183 residue of the human endostatin
described by O'Reilly et al (1997) with an intact N-termi-
nus (HSHRDFQ...), preceded by the secretion signal pep-
tide of the human IL-2. The Ad.Adapt.Luc is a
recombinant adenoviral vector in which the E3 region of
Ad5 is retained and the luciferase gene replaces the E1
region. The Ad5 Adapt empty is identical to Ad5 Adapt luc
except that it does not encode any transgene.
All vectors were produced on PER.C6™ using standard
procedures [35]. Infectious units (iu)/ml were determined
by end point cytopathogenic effect (CPE) assay on 911
cells [37]. Viral particles were determined by HPLC [38].
The particle to infectious unit ratio was always lower than
10.
Organ lysate and Luciferase activity assay
Animals were sacrificed by an overdose of isoflurane and
whole organs were removed, frozen in liquid nitrogen and
stored at -80°C. The whole gastrocnemius muscle or a
piece of the right lobe of the liver were homogenised in
phosphate buffered saline pH 7.8 using a blender. To lyse
the cells, DTT (SIGMA, The Netherlands) (1 mM) and Tri-
ton x-100 (0.1%) (Merck, The Netherlands) were added.
After centrifugation at 10,000 rpm for 10 min, 20 µl of the
supernatant was added to 100 µl of luciferase assay sub-
strate (Promega, The Netherlands). Relative light units
(RLU) were determined for 30 s using a luminometer
(Lumat 951, Wallac, Belgium). The amount of protein in
the extracts was determined using a commercial kit (Bio-
Rad laboratories, The Netherlands) based on the Cooma-
sie brilliant blue G250 binding assay developed by Brad-
ford [39]. The level of luciferase activity in the tissue
homogenates was expressed in RLU / mg protein. The
background level of this assay is <1000 RLU/mg protein
and was defined by measuring luciferase activity in organs
of non treated rats.
Plasma assays
For assay of plasma creatine phosphokinase (CPK), hEn-
dostatin, ATF and mhATF-BPTI, animals were anaesthe-
tised with isoflurane, bled by tail vein cut and the blood
was collected in EDTA tubes.
An mhATF-BPTI enzyme-linked immunoabsorbent assay
(ELISA) was developed by Dr. P. Quax (Gaubius Institut,
TNO-PG, Leiden), using a monoclonal antibody specific
for the ATF as the capture antibody and a polyclonal anti-
body directed against BPTI as the detector antibody [36].BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/11
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As a standard we used medium of Ad5 Adapt mhAB
infected CHO cell culture in which the mhATF-BPTI con-
centration was determined by an urokinase ELISA. Secre-
tion of human endostatin in plasma was routinely
determined using a commercial ELISA kit (InvivoGen, CA,
USA) according to the manufacturer's procedure.
Real Time PCR analysis for viral DNA
The amount of adenoviral genomes per cell was deter-
mined by a multiplex real-time polymerase chain reaction
[40]. Real-time PCR is based on the 5'-3' nuclease activity
of AmpliTaq Gold polymerase, which allows it to cleave
fluorogenic probes resulting in fluorescence. The amount
of fluorescence obtained during the PCR reaction is repre-
sentative to the amount of amplified DNA.
Total DNA of transduced rat organs was extracted by using
a DNeasy Tissue Kit (Qiagen). The kit efficiency was veri-
fied by measuring the recovery of plasmid DNA mixed
from a liver lysate. We confirmed that 80% of the total
DNA can be extracted from liver samples. To amplify the
adenoviral DNA, specific primers (Ad5Clip-F:
5'CGACGGATGTGGCAAAAGT3' and Ad5Clip-R:
5'CCTAAAACCGCGCGAAAA3') were designed by using
the Primer Express Software (Perkin-Elmer, Foster City,
CA, USA). A fluorogenic probe (Ad5Clip-Pr: 5'-VIC-CAC-
CGGCGCACACCAAAAACG-TAMRA-3') was also
designed by the Primer Express Software. To determine
the amount of cellular DNA present in the sample a sec-
ond pair of primers and a FAM-probe specific for 18S
rDNA [40] were used. The PCR reaction mixture consisted
of 1x buffer A (Perkin-Elmer), 3 mM MgCl2, 200 µM
dNTPs, 90 nM of each adenovirus primer, 100 nM of each
18S rDNA primer, 200 nM of each probe, 0.6 U AmpliTaq
Gold polymerase (Perkin-Elmer) and 5 µl of total DNA
sample. As a standard, to determine the amount of aden-
oviral genomes and cellular DNA, a plasmid containing
approximately 5000 bp of the left part of the Ad5 genome
(pAdapt) was mixed with cellular DNA extracted from
A549 cells. The PCR reaction was initiated with a hot start
at 95°C for 10 min and involved 45 cycles of 15 s at 95°C
and 1 min at 60°C.
Northern Blot
In case of intramuscular administration, the animals were
sacrificed 2 days after vector administration and the whole
gastrocnemius muscle was immediately collected and
snap frozen in liquid nitrogen. The complete muscle was
cut and homogenised in Trizol reagent (Gibco Life Tech-
nologies) using a blender. In case of cell cultures, the cells
were harvested 2 days after the infection and directly
homogenised in Trizol reagent. Total RNA was isolated
from the muscle tissue or the cell lysate homogenate by
using the method developed by Chomoczynski and
Sacchi [41]. Briefly, chloroform was added and the
aqueous phase containing the RNA was recovered. RNA
was precipitated with isopropyl alcohol and the pellet was
resuspended in RNase free water. The RNA and DNA con-
tent were measured by spectrophotometric analysis.
The quantity of RNA loaded was 20 µg as determined by
spectrophotometry. Both in the muscles as in the cell
lines, the RNA loaded represents a similar proportion of
the total RNA extracted. The RNA was run on a 1% agarose
gel and transferred onto Hybond N+ membrane by over-
night transfer. The RNA was then fixed by UV irradiation.
The hybridisation was performed overnight with one
stranded [32P]α-dATF Luciferase probe (1800 bp). A X-ray
film (Kodak) was exposed to the membrane for 24 h and
afterwards the membrane was scanned in a phosphorim-
ager for quantification. Then the membrane was stripped
15 min at 65°C and prehybridised with salmon sperm
DNA. Then a second hybridisation procedure was per-
formed with the [32P]α-dATF β-actin probe.
Pathology
The gastrocnemius muscle was removed 2 days after the
vector injection. The formalin-fixated muscle was then cut
in ten transversal pieces through its all length. A 10 µm
section was performed on all pieces and was stained with
haematoxylin and eosin. All sections were examined but
the quantification of the rhabdomyolysis was determined
only on 3 sections, 1 mm apart from each other, that are
corresponding to the middle of the length of the muscle
where the injection actually occurred. The total damage
score is a compilation of scores of apoptosis, hyaline
degeneration, myoblast proliferation, and inflammation
(Table 1).
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